Oxford Nanopore Prevails in Patent Ruling against Pacific Biosciences
Today the European Patent Office revoked Pacific Biosciences patent EP3045542 with claims to a single molecule sequencing process wherein two strands of DNA are linked by a connecting nucleic acid. The validity of the patent had been challenged by Oxford Nanopore.
The EPO ruled that the claims to a single molecule sequencing process were unsupported in the application and that the application only supported a template-directed synthesis sequencing method. As Pacific Biosciences were unwilling to accept this change, the patent was revoked.
The decision by the EPO is consistent with a recent decision by the International Trade Commission (ITC) to limit the claims of a related Pacific Biosciences US patent to template-directed synthesis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005733/en/
Contact information
Oxford Nanopore
Zoe McDougall
media@nanoporetech.com
Website: https://nanoporetech.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the
BEYOND Developments Reveals the Middle East’s First Forest District by the Sea, Featuring Talea as its First Residential Tower28.8.2025 23:03:00 EEST | Press release
As part of its ongoing commitment to shaping future-focused communities, BEYOND Developments has announced the launch of the Middle East’s first Forest District by the Sea, and Talea, the first in a series of residential towers that will bring this vision to life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828822584/en/ Talea by Beyond, a rare fusion of ocean, forest, and skyline views, where nature and design live in perfect harmony (Photo: AETOSWire) Set in Dubai Maritime City, this pioneering destination is a coastal haven centered on nature, wellness, and sustainability. By championing this nature-first approach, BEYOND Developments supports Dubai’s transformation into a global leader in sustainable, resilient urban living, aligned with the Dubai 2040 Master Plan, Net Zero 2050, and D33 Agenda. According to Adil Taqi, CEO of BEYOND Developments, this launch marks more than the beginning of a new residential offeri
Lattice to Showcase Industrial IoT and Security Innovation Leadership at FPGAworld Conference 202528.8.2025 23:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its participation in the upcoming FPGAworld Conference 2025, taking place on Sept. 9, 2025 in Sweden. As part of the conference’s technical program, Lattice will deliver presentations and host a demo showcase focused on advanced Industrial IoT and secure system design based on Lattice FPGAs. Who: Lattice Semiconductor What / When (GMT+2): Sept. 9, 2025 Demo showcase Presentations (Track: 12:50 – 2:05 p.m.): Industrial IoT Challenges and Solution for Real Time Communication Building High Security Systems with Lattice FPGAs Where: FPGAworld Conference, AFRY, Frösundaleden 2A, 169 70 Solna, Sweden The FPGAworld Conference is an international forum for researchers, engineers, teachers, students, and hackers. It covers topics such as complex analog/digital/software FPGA SoC systems, FPGA/ASIC-based products, educational & industrial cases, and more. Supporting Resources For more information about Lattic
KEO World Inc. announces Business Combination of its Global Trade Card (GTC) program with MAHA Capital28.8.2025 22:43:00 EEST | Press release
KEO World Inc., a lending fintech infrastructure platform for embedded credit B2B payments, today officially entered into a binding agreement to combine its GTC business with MAHA Capital AB, a publicly listed investment company on Nasdaq Stockholm. This transaction is designed to significantly strengthen our financial foundation and accelerate our global expansion. MAHA brings over USD 120 million in cash and liquid assets, while Keo investors will contribute an additional USD 35 million. Together, the combined company will have approximately USD 155 million of equity to deploy into the GTC program. As part of its growth strategy, the combined entity also intends to pursue a dual listing on Nasdaq in the United States, broadening investor access, enhancing liquidity, and positioning our company on the global stage. Under the agreement, Keo will transfer its GTC operations, including its SPV and Keo Puerto Rico LLC, which holds our Amex issuing license, to MAHA. Once completed, and sub
Biedermann Medtech Group Announces Transformation of U.S. Spine Market Approach and New Business Model28.8.2025 19:00:00 EEST | Press release
The Biedermann Medtech Group, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced a strategic transformation of its U.S. operations. Biedermann will expand its focus beyond product distribution to a broader platform of integrated services and solutions designed to reshape its U.S. business model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828746562/en/ As part of this transition, Biedermann Motech will discontinue to directly distribute its product lines of advanced solutions for spinal and extremity surgery in the U.S. market in the near future. This decision follows a comprehensive and detailed review of market dynamics and recent macro-economic developments. In the next phase of this transformation, Biedermann Motech will leverage its strategic partnership with intellectual property powerhouse and recognized innovation leader Biedermann Technolog
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom